Linezolid in the treatment of subjects with complicated skin and soft tissue infections proven to be due to methicillin-resistant Staphylococcus aureus

Trial Profile

Linezolid in the treatment of subjects with complicated skin and soft tissue infections proven to be due to methicillin-resistant Staphylococcus aureus

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2015

At a glance

  • Drugs Linezolid; Linezolid; Vancomycin
  • Indications Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Aug 2012 Actual patient number changed from 1052 to 1077 as reported by ClinicalTrials.gov record.
    • 12 Sep 2009 Results of a post hoc analysis were presented at ICAAC 2009.
    • 17 Dec 2008 Results were reported at ICAAC/IDSA 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top